Optimal Treatment for Active Systemic Lupus Erythematosus

Anca Askanase, MD, MPH; Joan Merrill, MD


January 17, 2023

Systemic lupus erythematosus (SLE) is a heterogenous disease, and therapies are used to prevent flares, preserve organ function, and manage comorbidities. In recent years, new drugs, including belimumab and anifrolumab, have shown some success in disease control in this patient population. However, clinical trials have yet to answer how best to identify the right patient to treat with biologic therapy and when to start medication.

Rheumatologist Dr Anca Askanase from Columbia University Medical Center is joined by her friend and colleague Dr Joan Merrill from the University of Oklahoma Health Sciences Center to discuss optimal treatments for patients with active SLE, including European Alliance of Associations for Rheumatology recommendations, therapeutic combination considerations, and current clinical trial data.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.